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PURPOSE: American football athletes are exposed to subconcussive impacts over the course of the 
season resulting in elevations in serum neurofilament light (NFL), a biomarker of axonal injury. 
Docosahexaenoic acid (DHA) has been reported to reduce axonal trauma associated with traumatic 
brain injury in rodent models. However, the optimal dose in American football athletes is unknown. This 
study examined the effect of differing doses of DHA on serum NFL over the course of a season of 
American football. 
 
METHODS: In a randomized, double-blind, placebo-controlled, parallel design, 81 National Collegiate 
Athletic Association Division I American football athletes were assigned to ingest either 2, 4, 6 g·d of 
DHA or placebo. Blood was sampled at specific times over the course of 189 d, coincident with changes 
in intensity, hours of contact, and likely changes in head impacts. Standardized magnitude-based 
inference was used to define outcomes. 
 
RESULTS: DHA supplementation increased plasma DHA in a dose-dependent manner (2 g·d: mean 
difference from baseline; ±90% CL; 2 g·d: 1.3; ±0.6; 4 g·d: 1.6; ±0.7%; 6 g·d: 2.8; ±1.2%). Serum NFL 
increased to a greater extent in starters (area under the curve, 1995 ± 1383 pg·mL) versus nonstarters 
(1398 ± 581 pg·mL; P = 0.024). Irrespective of dose, supplemental DHA likely attenuated serum NFL 
coincident with increases in serum NFL by likely small and moderate magnitude (effect size = 0.4-0.7). 
 
CONCLUSIONS: Findings from this study, the first large-scale study examining potential prophylactic use 
of DHA in American football athletes, include identification of optimal dose of DHA, suggesting a 





American football is associated with the highest incidence of concussion (16), often used 
interchangeably with the term mild traumatic brain injury (mTBI), among team sports (19).  This is not 
surprising, given that during play American football athletes are routinely exposed to head impacts, 
which result in head rotational acceleration/deceleration forces (inertial loading) and propagation of 
force through the brain (9, 10, 14, 15, 17, 40, 42). These mechanical forces are known to result in 
stretching of white matter, which leads to diffuse axonal injury (1, 11), a characteristic feature of mTBI.  
Using magnetic resonance imaging (MRI) in conjunction with diffusion tensor imaging (DTI), Davenport 
et al. (18) demonstrated that a single season of American high school football resulted in changes in MRI 
indicative of axonal injury in the absence of a concussion diagnosis.  This was the first study to 
demonstrate that the sub-concussive impacts sustained by American football athletes likely result in a 
measurable physiological response.   
Interestingly, elevations in cerebrospinal fluid (CSF) neurofilament light polypeptide (NFL) have 
been reported in boxers sustaining concussive or sub-concussive head impacts (32, 33, 49).  
Neurofilaments are abundant in key intermediate fibers in neurons and major components of the axonal 
skeleton(21, 38) thus, marked elevations indicate a level of axonal injury.  While boxers deliver punches 
with high impact velocity, a lower head injury criterion due to shorter duration acceleration and 
translational acceleration has been reported when compared to American football (46). Thus, it is likely 
that the sub-concussive impacts sustained by American football athletes also result in a measurable 
change in NFL.  Indeed, using single molecule array (Simoa), which allows quantification with an increase 
in analytical sensitivity over that of conventional assays(39), we found that a season of American 
football results in measurable elevations in serum NFL coincident with those times in which an increase 
in the number of head impacts was likely (36).  This is of great importance, given that in the absence of 
reporting or characteristic display of symptoms an athlete may play before full recovery, which may 
further subject the athlete to injury and increase the likelihood of damage to the brain (41).   
In their recent position statement, the American Medical Society for Sports Medicine suggested 
that despite advancements in protective equipment (47), those changes have not been shown to reduce 
the incidence and/or severity of concussion in sport (23).  Our recent findings (36) and those of 
Davenport et al. (18) highlight the need for a different approach.  Nutritional supplementation, 
specifically docosahexaenoic acid (DHA, 22:6n-3), the principle n-3 long-chain polyunsaturated fatty acid 
(n-3 LCPUFA) in brain tissue (25) has received considerable attention as a possible intervention to 
mitigate the pathology associated with mTBI.  Prior investigation of traumatic brain injury (TBI) in animal 
models has demonstrated that supplemental DHA attenuates axonal damage when administered prior 
to insult (6, 43).  The typical American diet is scarce in both DHA and the n-3 LCPUFA eicosapentaenoic 
acid (EPA, 20:5n-3), with an estimated combined intake of about 100 mg•day-1 (20).  While it is known 
that supplemental DHA results in an increase in plasma DHA in a dose dependent manner up to 
approximately 2 g•day-1 in the average population (5), American football athletes are larger than the 
average and most athletes (48) and participate in heavy physical training, which is known to affect fatty 
acid composition (35). Therefore, larger doses may be necessary. 
 This study sought to examine the effect of differing doses of supplemental DHA on serum NFL 
over the course of a season of American football.  We have previously reported that American football 
results in measurable elevations in serum NFL over the course of the season (36).  We hypothesized that 
American football athletes would require higher doses of supplemental DHA due to their larger size and 
physical activity.  Further, given reports of supplemental DHA reducing axonal injury in rodent models of 
TBI (6, 43), we hypothesized that supplemental DHA would attenuate the increase in serum NFL 
observed.    
Methods  
Subjects.  This study was conducted according to the Declaration of Helsinki guidelines.  All procedures 
involving human subjects were approved by the Institutional Review Board of Texas Christian University 
for use of human subjects in research (protocol no. 1404-68-1404).  Written consent was obtained from 
all subjects. 
 All athlete volunteers were cleared to participate in university athletics as determined by the 
team physician.  Exclusion criteria included chronic anti-inflammatory or anti-hypertensive medication 
use, medications for blood lipids, fish oil or omega-3 fatty acid supplementation, and consumption of 
more than 2 servings of fish per week.  Athletes injured or unable to participate in regularly schedule 
conditioning or competitions were also excluded.  A consort diagram is provided in Figure 1 outlining 
reasons for dropout and/or exclusion.  A total of 81 athletes completed the study.  
Insert Figure 1 here 
Study Design.    A randomized, double-blind, placebo-controlled, parallel design study was employed to 
examine the effect of differing doses of DHA on plasma fatty acids and serum NFL over the course of a 
season (189 days) of American football to include off-season summer conditioning (57 days), pre-season 
camp (23 days), and the competitive season (109 days).  Prior to the start of summer conditioning, the 
American football athletes were randomly assigned to ingest an oil-mixture providing 2 g•d-1, 4 g•d-1 
DHA, 6 g•d-1 DHA, or placebo, corn oil, for the study duration.  Blood was sampled at specific intervals 
over the course of the 189 day intervention coincident with changes in intensity, hours of contact, and 
likely changes in head impacts. Upon reporting for summer conditioning, a baseline blood sample was 
taken when volunteers returned from a period of no contact (9 weeks) (Baseline; T1). Summer 
conditioning consisted of strength and conditioning workouts Monday through Friday for approximately 
two hours per day.  A second sample was obtained at the conclusion of summer training prior to pre-
season training camp (Pre-Camp; T2). In the time between baseline and the start of training camp no 
head to head contact took place, but many of the athletes elected to participate in non-supervised 
seven on seven practices, which involve no contact or equipment and occurred approximately twice per 
week for one-hour. A third sample was collected following pre-season training camp (Post-Camp; T3).  
Camp began with three non-contact practices in shorts and helmets, one practice in helmet and 
shoulder pads, followed by full gear practices.  The first five days, practices were held once per day.  
Thereafter, two-a-day practices were held every other day for the remainder of camp.  One day a week 
(Sunday) the athletes were off from training and practice.  The remaining blood samples were taken 
throughout the competitive season on the Monday following a Saturday game (48 hours) (T4-T8).  The 
first two samplings (T4, T5) occurred during Pre-conference play, whereas the last three (T6-T8) 
occurred during conference play.   During the competitive season athletes underwent a one hour shorts 
and helmets practice on Sunday, Monday was an off day, followed by full pad practice on Tuesday, 
helmets and shoulder pads on Wednesday, Thursday and Friday were shorts and helmets only (no full 
contact, incidental only). During the competition season, tackles were not taken to the ground, hit and 
wrap only.  Additionally, athletes would perform three strength and conditioning sessions per week. The 
maximum (median) number of head impacts per season for an NCAA American football athlete has been 
reported to range from 15.6 to 24 (4.8 to 7.5) and 58.5 to 86.1 (12.1 to 16.3) for practices and games, 
respectively (14). All samplings throughout the season occurred within 14 - 28 day intervals, with no 
sampling occurring more than 28 days from the previous one.    
Supplementation.  Prior to the beginning of summer training, a one-hundred thirty man roster of 
prospective volunteers from a National Collegiate Athletic Association (NCAA) Division I American 
football team was provided to research personnel.  Potential participants were randomized by player 
position provided by coaching staff and subsequently randomized to one of four treatment groups (2 
g•d-1 DHA, 4 g•d-1 DHA, 6 g•d-1 DHA, or placebo) using a random number generator.  The algal DHA used 
in this study (DHA-S oil, DSM Nutritional Products; Columbia, MD) was derived from Schizochytrium sp. 
containing 35-45% DHA by weight.  Wesson ® corn oil, containing < 0.1% DHA, was used as the placebo 
and in the 2 g•d-1 and 4 g•d-1 DHA oil-mixtures to ensure equal volume. To ensure proper dose the lower 
limit (35%) of DHA content by weight contained in the DHA-S oil was used for calculations.  The oil 
mixture was weighed to the nearest 0.1 g on food scales (Ohaus CS-200; Parsippany, NJ, USA).  All 
mixtures were flavored with artificial flavoring as a masking agent.  Stability of oil mixture was verified 
by procedures outlined in “Fatty acid composition of plasma” for preparation up to 7 days prior to 
delivery.  The fatty acid composition for both oils is shown in Table 1.   
Insert Table 1 here 
Participants were advised as to which foods were high in DHA and asked to limit servings to no 
more than 2 per week during the study. Supplement adherence was monitored daily via visual 
supervision by the same research personnel. To ensure compliance, supplement was given only on days 
when the participants reported to the training facility resulting in participants receiving supplement for 
5 days, 7 days, and 5 days per week for summer training, pre-season camp, and the competitive season, 
respectively. Supplement compliance was set at ≥80% for each individual over the course of the study.  
Days that supplement was not given were not taken into account for calculating compliance.   
Blood sampling and preparation.   The night prior to each blood collection, participants were 
verbally reminded to ingest only water after 2200.  On the day of blood sampling, participants reported 
to the athletic training facility after an overnight fast (≥ eight hours), supine blood samples were 
collected via venipuncture from the antecubital fossa region using standard, sterile phlebotomy 
procedures.  To prevent any substantial clinical differences in subsequent blood draws, short-term stasis 
was prevented by immediate removal of the tourniquet following observable blood flow (27).  Blood 
samples were collected in spray-coated K2 ethylenediaminetetraacetic acid (EDTA) vacutainer tubes and 
serum vacutainer tube with no additive (BD Diagnostics, Franklin Lakes, NJ, USA). Vacutainer tubes were 
kept on ice prior to blood collection and immediately placed on ice following blood collection.  All 
samples were centrifuged at 2,000 g for 30 minutes at 4o Celsius (Beckman Coulter, Allegra X-15R, Brea, 
CA, USA) within 30 minutes of collection.  Aliquots of serum, plasma, and red blood cells, collected via 
sterile pipette from center of the red blood cell pack within the EDTA vacutainer tubes, were 
immediately transferred to a pre-labeled polypropylene vials . 
Serum Neurofilament Light (NFL).  Serum NFL levels were determined using the NF-Light kit from 
UmanDiagnostics (UmanDiagnostics, Umeå, Sweden), transferred onto the Simoa platform using a 
homebrew kit (Quanterix Corp, Boston, MA, USA). The lower limit of quantification was 1.95 pg/mL. The 
analyses were performed by a board-certified laboratory technician in one round of experiments using 
one batch of reagents with intra-assay coefficients of variation below 10%. 
Fatty acid composition of plasma.  Total lipid was extracted and methylated according to previously 
described procedures (2, 22, 31).  Fatty acid methyl esters (FAME) were analyzed with a Varian gas 
chromatograph (model CP-3800 fixed with a CP-8200 autosampler, Varian Inc.; Walnut Creek, CA) 
equipped with a fused silica capillary column CP-Sil88 (100 m x 0.25 mm i.d.; Chrompack Inc., 
Middleburg, The Netherlands) (22).  Individual FAME were identified using genuine standards (Nu-Chek 
Prep, Inc., Elysian, MN) and response factors were calculated from a library of commercially available 
methyl esters of palmitic, oleic, linoleic, and arachidonic acid from the same manufacturer.  Data are 
expressed as percent (%) total fatty acids. 
Statistical Analyses.  A priori power analysis was conducted using G*Power version 3.1.9 to determine 
the minimum sample size required to find significance in changes in proportion DHA in total plasma fatty 
acids with a desired level of power set at .80, an α-level at .05, and a standardized effect size calculated 
from previous pilot study.  It was determined that total of 20 subjects were needed to ensure adequate 
power. 
 The effects of supplementation and time on variables of interest were estimated from a mixed 
model analysis of variance (ANOVA) in SPSS V.22 (IBM Corporation; Armonk, NY).   From that model, 
estimates and uncertainty of the large-sample effect size for the effect of treatment and time on 
dependent measures were derived from the model to allow a magnitude-based approach to inference 
(24).  Effect sizes were calculated and a modified classification system (trivial, 0.0 – 0.2; small, 0.2 – 0.6; 
moderate, 0.6 – 1.2; large, 1.2-2.0; very large, >2.0; extremely large, >4.0) was used to further interpret 
the magnitude of change.  The probability (likelihood) that a contrast was at least greater than the 
smallest threshold, calculated as the standardized change of 0.2 times the between subject standard 
deviation at baseline among all treatments was qualified as follows: 0.5%, almost certainly not; 0.5–5%, 
very unlikely; 5–25%, unlikely; 25–75%, possible; 75–95%, likely; 95–99.5%, very likely; 99.5%, almost 
certain. In the case where the majority (>50%) of the confidence interval (CI) lies between the threshold 
for substantiveness and the probability of benefit or harm is <5.0%, the effect was qualified trivial with 
the appropriate likelihood qualifier.  
Results 
Compliance and Reported Side Effects.  Mean compliance over the course of the 189 day intervention 
was 94%, 90%, 95%, and 91% for 2 g•d-1,  4 g•d-1 DHA, 6 g•d-1 DHA, and placebo; respectively. Side 
effects of supplemental DHA included initial gastrointestinal distress, poor palatability, and belching.   
Supplemental DHA Increases Plasma DHA in Dose-Dependent Manner. The change from T1 to T8 in 
proportion DHA, EPA, and arachidonic acid (ARA) of total plasma fatty acids is shown in Figure 2A-C, 
respectively.  DHA supplementation increased proportion of DHA in plasma fatty acids from baseline by 
a most likely large magnitude (ES = 1.74 to 2.17) in a dose-dependent manner.  Clear contrasts were 
observed when examining change from baseline in each dose, with very likely and most likely 
substantially greater delta in the 6 g•d-1 DHA treatment group, when compared to 4 g•d-1 (ES = 0.7; p = 
0.006) and 2 g•d-1 (ES = 1.0; p = 0.001).   Supplemental DHA also increased plasma EPA in the 4 g•d-1 (ES 
= 0.6; p = 0.130) and 6 g•d-1 (ES = 1.7;p < 0.001) treatment groups.     However, clear contrasts were only 
observed in the 6 g•d-1 dose (mean difference; ±90% CI; 0.23; ±0.15%) when change from baseline was 
compared to placebo (ES = 0.9; p = 0.016). ARA decrease in all DHA treatment groups, with the most 
substantial change observed in the 2 g•d-1 and 4 g•d-1 treatment groups (ES = 1.2; p = 0.001 and ES = 1.2; 
p = 0.002, respectively). 
Insert Figure 2 here 
 
Serum Neurofilament Light (NFL) Increases in Starters.  Serum NFL increased substantially over the 
course of the season in those participants categorized as starters (Figure 3A).  The observed increase 
occurred coincident with changes in intensity and hours of contact. The Post-Camp (T3) serum NFL 
increase observed was very likely, but small in magnitude in starters (ES = 0.4; p = 0.001) compared to 
baseline (T1).  As expected, a similar albeit smaller increase was observed in non-starter (ES = 0.3; p = 
0.043) as those in this category would have experienced the most contact during the time from Pre-
Camp (T2) to Post-Camp (T3).  All other contrasts in the non-starters were trivial.  However, serum NFL 
remained elevated the remainder of the competition season in starters, with a further very likely 
increase of moderate magnitude occurring at T6 (ES = 0.6; p < 0.001), coincident with conference play.  
A further increase was noted at T7 (ES = 0.8; p < 0.001), which remained elevated to the end of the 
competitive season (ES = 0.7; p < 0.001).  The increase observed over the course of the study in starters 
resulted in substantial differences noted over the course of the study when compared to non-starters 
(Table 3).  Similarly, the area under the curve calculation determination resulted in a very likely 
difference of moderate magnitude (600; ± 430 pg•mL-1•day; ES = 0.6; p = 0.024) between starters (1995 
± 1383 pg•mL-1•day) and non-starters (1398 ± 581 pg•mL-1•day). 
 
Insert Figure 3 here 
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Supplemental DHA Attenuates Increase in Serum NFL.  Due to the lack of change in serum NFL, those 
athletes categorized as non-starters were excluded from further analyses.  The effect of DHA 
supplementation irrespective of dose (collapsed across treatments) compared to placebo is presented in 
Figure 3B whereas Figure 3C shows the effect of the different doses on serum NFL over the course of 
football season.  When collapsed across all treatment groups, supplemental DHA likely attenuated serum 
NFL Post-Camp (p = 0.070; Table 3), coincident with Post-Camp (T3) in which a substantial increase in 
serum NFL was observed in starters.  During conference play, when a second substantial increase in serum 
NFL was observed amongst starters, supplementation with DHA resulted in a likely lowering effect 
compared to placebo (p = 0.144, T6), which continued through the end of the study when a likely lowering 
of serum NFL was observed in those supplementing with DHA compared to placebo (p = 0.022, T7; p = 
0.012, T8).  Examination of the effect of the differing doses on serum NFL resulted in fewer athletes in 
each group.  However, we observed a likely and very likely substantial lowering effect of 2 g•d-1 DHA 
compared to placebo over the course of the study. In those supplementing with 4 g•d-1 and 6 g•d-1 DHA, 
all contrasts were unclear with the exception of the final time point in which a likely substantial lowering 
effect was observed in those in the 4 g•d-1 treatment.  
 
Insert Table 3 here 
 
Discussion  
 In this study, we examined the effect of differing doses of DHA on plasma fatty acids and serum 
NFL, a biomarker of head trauma, over the course of a season in American football athletes.  This study 
provides novel data specific to the optimal dose of DHA in American football athletes.  Further, the data 
presented herein demonstrate that a season of American football is associated with some level of sub-
concussive injury, which results in a measurable increase in a marker of axonal damage.  Most 
importantly, we report for the first time that supplemental DHA, irrespective of dose, likely attenuates 
elevations in serum NFL coincident with those times in which an increased number and magnitude of 
head impacts is likely in American football athletes.   
The neuroprotective effects of supplemental DHA observed in rodent models of TBI are most 
evident when doses are high (~40 mg•kg-1•day) (7), corresponding to a dose of approximately 4.3 g•kg-
1•day in today’s collegiate American football athlete (28, 37).   However, in analyzing the dose-response 
effect, Arterburn et al. (5) reported a dose-dependent relationship in which plasma DHA increases up to 
a dosage of approximately 2 g•day-1; above this dose, the authors reported only incremental increases 
are observed as saturation is approached (5).   The finding of a dose-response effect is in agreement 
with those findings (5); however, the substantial increases observed at the 4 g•d-1 and 6 g•d-1 dose, 
suggests that higher doses may be necessary as no apparent plateau was noted.  This is not surprising 
given the large size of American football athletes compared to the general population and other athletes 
(48).  Despite having relatively high body mass, the subjects in those studies analyzed by Arterburn et al. 
(2) were lower than those reported in American football athletes (28, 37). Further, American football 
athletes undergo rigorous physical training physical activity, which is known to influence plasma fatty 
acid composition (35).  
The lack of an observable increase in EPA in those receiving 2 g•d-1 combined with a lack of clear 
contrasts when comparing change from baseline in those receiving 4 g•d-1 and placebo supports the 
assertion that a higher dose may be necessary in American football athletes.   While retroconversion of 
DHA to EPA is regularly observed (5, 30), Mori et al. (29) reported a small non-significant increase in EPA 
following a 6-week intervention in which overweight men received supplemental DHA in a dose of 4 g•d-
1 .  Interestingly, the largest decrease in ARA occurred in those receiving 2 g•d-1.  Though a similar dose 
dependent reduction in ARA is typically observed, the response has been reported to be variable when 
examining a number of studies (5).  This study contributes important new information specific to 
optimizing DHA supplementation in American football athletes.    
  It is well known that American football athletes are exposed to head impacts that vary in 
number and magnitude over the course of a season (14).  Further, those routine head impacts sustained 
result in rotational acceleration/deceleration and propagation of force through the brain (9, 15, 40), 
impacts known to cause diffuse axonal injury (1, 11).  It has been suggested that NFL, albeit in CSF, is one 
of the most sensitive biomarkers of head trauma, specifically axonal injury (32, 49, 50).  Recently, Al 
Nimer et al. (3) reported that a significant relationship exists between CSF NFL and serum NFL in severe 
TBI.  As such, elevations of NFL in peripheral blood would indicate some level of axonal injury.   Thus, the 
finding of marked elevations following periods in which an increase in number and magnitude of head 
impacts was likely (14) suggests that some level of axonal damage occurs in American football athletes 
over the course of a season in the absence of a concussion diagnosis.  
  Indeed, Davenport et al. (18) reported that the risk weighted exposure (RWE), a metric defined 
as collected risk of concussion over the course of a season(45), showed strong associations with 
diffusion tensor imaging (DTI) scalars in American football athletes at the high school level in the 
absence of a concussion diagnosis.   Most studies using DTI in TBI and mTBI report that the changes 
reported in those specific scalars identified by Davenport et al. (18) result from axonal injury (4, 34).  The 
number of high-level impacts are more frequent in collegiate compared to high school players (42); thus, 
our data support that the sub-concussive impacts sustained by collegiate American football players 
results in some degree of axonal injury.  The primary inferential limitation to the current data is the lack 
of an outcome measure related to the actual number of head impacts sustained over the course of the 
season. As a result, our ability to discern if the elevations in serum NFL were a result of axonal damage 
caused by head impacts or from another source, such as muscle is limited. However, despite 
participating in practice over the course of the season, serum NFL did not vary in those categorized as 
non-starters, suggesting that the elevations observed herein were in fact a result of impacts to the head. 
 Perhaps the most novel finding of the current study was that supplemental DHA likely 
attenuated the increase observed in serum NFL.  Interestingly, the lowest dose (2 g•d-1) appeared to 
produce the most marked reductions in serum NFL compared to placebo. However, inference about the 
differing doses is limited by the number of starters in each group.  Previous studies in rodent models of 
TBI support the possibility that DHA reduces markers of axonal injury (6, 43). Fewer numbers of β-
amyloid precursor protein (APP)- positive axons, a marker of axonal injury, were reported in animals 
receiving supplemental DHA for 30 days prior to impact acceleration injury (6). More recently, Schober 
et al. (43) examined the effect of DHA on DTI indices of white matter injury using an established model 
for pediatric TBI, controlled cortical impact (CCI) (26).  DHA decreased the increment in radial diffusivity 
(RD) observed in the DTI following CCI, increased RD is correlated with histologic axonal damage(44).  
Thus, our data are in support of previous studies in which DHA has been shown to provide 
neuroprotective effect in rodent models of TBI.  While a number of mechanisms have been proposed, 
the exact mechanism underlying the neuroprotective effects of DHA are as of yet unknown. Our findings 
are in support of those findings in which DHA attenuated markers of axonal injury in rodent models.  
However, we report on the potential effectiveness of DHA for axonal injury caused by sub-concussive 
impacts in American football athletes, the first to date.    
   The current study has several limitations.  First, our results are limited by the sample size, 
particularly as it relates to starters.  Based on preliminary data and the absence of an optimal dose 
regimen for DHA for the larger American football athlete at the time of design, we sought to 
experimentally define an optimal dosage.  In doing so, this limited the number of starters in each dose 
treatment group making interpretation of the optimal dose for neuroprotective effect of DHA difficult.  
Still, as mentioned in the Results, when collapsed across treatment the likely lowering effect of DHA on 
serum NFL was apparent, though this may have been attributed to those athletes receiving 2 g•d-1.  
Second, the lack of an outcome measure for number of head impacts limits inference as to the 
origination of NFL appearing in peripheral blood.  No increase was observed in the non-starters 
participating in strenuous practice which suggests that NFL was indeed from head impacts.  Further 
study is warranted to examine the relationship between the number of head impacts and serum NFL 
levels in this population.  The inclusion of DTI would provide additional support.     
 In conclusion, the data presented herein demonstrate that American football athletes likely 
require a higher dose of DHA than the average population.  Further, serum NFL increases in those 
categorized as starters coincident with those times in which the number of head impacts likely 
increases.  Most importantly, we report for the first time that supplemental DHA likely attenuates the 
increase in serum NFL suggesting a neuroprotective effect of DHA, specifically as it relates to axonal 
injury.  The latter agrees with previous reports of the neuroprotective effect of DHA in rodent models of 
TBI.  Our study contributes important information on the effects of DHA on biological markers of head 
trauma in a population known to sustain a significant number of head impacts.  Given the potential of 
DHA to provide neuroprotection and the fact that it is well-tolerated and safe at any age, further study is 
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Figure 1.  Consort diagram outlining reasons for exclusions.  DHA, docosahexaenoic acid. 
 
Figure 2.  Effect of docosahexaenoic acid (DHA) supplementation on proportion arachidonic acid (A), 
eicosapentaenoic acid (EPA) (B), and DHA of total plasma fatty acids in all treatment groups.;  Threshold 
for smallest substantial change calculated as 0.2 times baseline SDbetween; Likelihood is shown as 
increased number of symbols (+)relative to baseline in each treatment group:  +possible, ++ likely, +++ 
very likely, ++++ most likely.  All data are mean.  A magnitude-based summary of statistical contrasts 
among treatments with corresponding mean ± SD is shown in Table 2.   
 
Figure 3.  (A) Changes in serum neurofilament light (pg•mL-1) over the course of the study in starters and 
non-starters;  (B & C) Effect of supplemental docosahexaenoic acid (DHA) on serum neurofilament light 
(% change from baseline) over the course of the study in starters;  (B) Collapsed across all doses (A) and 
(C) separated by dosage; Threshold for smallest substantial change calculated as 0.2 times baseline 
SDbetween; Likelihood is shown as increased number of symbols (+ used for example) and represented by 
unique symbol:  (+)relative to baseline, (*) relative to placebo.   +possible, ++ likely, +++ very likely, ++++ 
most likely.  All data are mean.  A magnitude-based summary of statistical contrasts between starters 
and non-starters with corresponding mean ± SD is shown in Table 2 and statistical contrasts comparing 
each dose to placebo with corresponding mean ± SD is shown in Table 3.   
 
